This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Top Stocks Reports for McDonald's, AbbVie & Altria
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), AbbVie (ABBV) and Altria (MO).
Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
by Zacks Equity Research
Gilead Sciences (GILD) names Roche's Daniel O'Day as the company's new Chairman and CEO.
Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800
by Zacks Equity Research
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day.
Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend
by Zacks Equity Research
Amgen (AMGN) hikes its quarterly dividend by 10%.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
by Zacks Equity Research
IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.
Gilead's (GILD) Harvoni and Descovy Get Approval in China
by Zacks Equity Research
Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.
J&J's Blood Cancer Drugs Succeed in Label Expansion Studies
by Zacks Equity Research
J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.
Roche Announces Positive Data on Venclexta/Venclyxto at ASH
by Zacks Equity Research
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.
AbbVie Settles With Pfizer for Humira Biosimilar in U.S.
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November
AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
by Zacks Equity Research
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.
Why Is AbbVie (ABBV) Up 17.5% Since Last Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Key Pharma Players With HIV Focus Ahead of World Aids Day
by Indrajit Bandyopadhyay
We take a look at some of the major pharma companies in the HIV market that are developing drugs to address the life-threatening disease.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $88.93 in the latest trading session, marking a +1.43% move from the prior day.
Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth
by Zacks Equity Research
Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
Roche, AbbVie Get FDA Approval for Venclexta Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets accelerated approval for Venclexta for the treatment of patients suffering from newly-diagnosed AML who are aged 75 years or older.
AbbVie (ABBV) Stock Moves -1.55%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $88.09, moving -1.55% from the previous trading session.
Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
by Zacks Equity Research
CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.
Should Value Investors Consider AbbVie (ABBV) Stock Now?
by Zacks Equity Research
Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
by Zacks Equity Research
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day.